FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 05, 2012
FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter - MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
September 19, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012 / Pharmacogenomics Reporter - ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter - CHMP Recommends Conditional Marketing Authorization for Pfizer's Leukemia Drug
January 23, 2013 / Pharmacogenomics Reporter